



Applicant's Docket No. MPI00-370P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Meyers, Rachel E.		
Application No.:	09/945,173	Group No.:	1635
Filed:	August 31, 2001	Examiner:	Angell, Jon
For:	47324, A NOVEL HUMAN G PROTEIN AND USES THEREFOR		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

☐ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☒ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.



Signature

Date: April 6, 2005

Sean Hunziker
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-370P1RM

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☒ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI00-370P1RM

FEE PAYMENT

3. ☒ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☐ Applicant believes no fee is due in connection with this submission.

Fee due \$180.00


METHOD OF PAYMENT OF FEE

4. ☐ Attached is a check in the amount of \$ _____ .
☒ Charge Account No. 501668 in the amount of \$180.00 .
☒ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

April 6, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820



Practitioner's Docket No. MPI00-370P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor application of:	Meyers, Rachel E.		
Application No.:	09/945,173	Group No.:	1635
Filed:	August 31, 2001	Examiner:	Angell, Jon
For:	47324, A NOVEL HUMAN G PROTEIN AND USES THEREFOR		

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Form PTO/SB/08A (substitute for Form PTO-1449) (1 page)
3. ☒ Form PTO/SB/08B (substitute for Form PTO-1449) (3 pages)
4. ☒ Copies of Listed Information Items Accompanying This Statement
5. ☒ Copy of International Search Report for PCT/US01/27197

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: April 6, 2005

Sean Hunziker
(type or print name of person certifying)

(Page 1 of 2)

04/12/2005 SDIRETA1 00000057 501668 09945173

01 FC:1806 180.00 DA

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

April 6, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray

Registration No. 47,066


40 Landsdowne Street

Cambridge, MA 02139

Telephone – (617) 551-3676

Facsimile – (617) 551-8820

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/945,173		
		Filing Date	August 31, 2001		
		First Named Inventor	Meyers, Rachel E.		
		Group Art Unit	1635		
		Examiner Name	Angell, Jon E.		
Sheet	1	of	3	Attorney Docket Number	MPI00-370P1RM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	CA	ALBERTS et al., Molecular Biology of the Cell, 1994, pages 206-207, 230-232, 641, Garland Publishing, Inc., New York.	
	CB	ALTSCHUL et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, 1997, 25(17):3389-3402.	
	CC	BOURNE et al., "The GTPase superfamily: a conserved switch for diverse cell functions", Nature, November 8, 1990; 348:125-132.	
	CD	CERIONE and ZHENG, "The Dbl family of oncogenes", Curr. Op. Cell Biol., 1996, 8:216-222.	
	CE	CHERFILS and CHARDIN, "GEFs: structural basis for their activation of small GTP-binding proteins", Trends Biochem. Sci., 1999, 24:306-311.	
	CF	GAMBLIN and SMERDON, "GTPase-activating proteins and their complexes", Curr. Op. Struct. Biol., 1998, 8:195-201.	
	CG	GRIBSKOV et al., "Profile Analysis", Meth. Enzymol., 1990, 183:146-159.	
	CH	GRIBSKOV et al., "Profile analysis: Detection of distantly related proteins", Proc. Natl. Acad. Sci. USA, July 1987, 84:4355-4358.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Please type a plus sign (+) inside this box → ☐



Substitute for form 1449B/PTO				Complete if Known	
				Application Number	09/945,173
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	August 31, 2001
				First Named Inventor	Meyers, Rachel E.
				Group Art Unit	1635
				Examiner Name	Angell, Jon E.
				Attorney Docket Number	MPI00-370P1RM
Sheet	2	of	3		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	CI	HALL, "The Cellular Functions of Small GTP-Binding Proteins", Science, August 10, 1990; 249:635-640.	
	CJ	KROGH et al., "Hidden Markov Models in Computational Biology Applications to Protein Modeling", J. Mol. Biol., 1994, 235:1501-1531.	
	CK	MATOUZAKI et al., "Small G-protein networks Their crosstalk and signal cascades", Cellular Signaling, 2000, 12:515-524.	
	CL	SCHEFFZEK et al. "GTPase-activating proteins: helping hands to complement an active site", Trends Biochem. Sci., July 1998, 23:257-262.	
	CM	SCHULTZ et al. "SMART, a simple modular architecture research tool: Identification of signaling domains", Proc. Natl. Acad. Sci. USA, May 1998, 95:5857-5864.	
	CN	SCHULTZ et al. "SMART: a web-based tool for the study of genetically mobile domains", Nuc. Acids Res., 2000, 28(1): 231-234.	
	CO	SONNHAMMER et al., "Pfam: A Comprehensive Database of Protein Domain Families Based on Seed Alignments", PROTEINS: Structure, Function and Genetics, 1997, 28:405-420.	
	CP	STULTZ et al., "Structural analysis based on state-space modeling", Protein Science, 1993, 2:305-314.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.





Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/945,173
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	August 31, 2001
		First Named Inventor	Meyers, Rachel E.
		Group Art Unit	1635
		Examiner Name	Angell, Jon E.
		Attorney Docket Number	MPI00-370P1RM
Sheet	3	of	3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	CQ	WHITEHEAD et al., "Retroviral transduction and oncogenic selection of a cDNA encoding Dbs, a homolog of the Dbl guanine nucleotide exchange factor", Oncogene, 1995, 10:713-721.	
	CR	NCI-CGAP., "ns66d03.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE: 1188581 3'. mRNA sequence," Dec 3, 1997, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on April 4, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov . GenBank Accession. AA662172	
	CS	SUGANO, S. et al., "Homo sapiens cDNA: FLJ22119 fis, clone HEP18852" Sep. 29, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on April 4, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov . GenBank Accession AK025772	
	CT	BIRREN et al., "Homo sapiens, clone RP11-44J3, complete sequence," Aug 13, 1999, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on April 4, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov . GenBank Accession AC009289	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.